Type 2 Diabetes Subtypes: Useful Biology or Premature Labels?

Two people can meet the same glucose criteria for type 2 diabetes and arrive there through different biology. One may have marked insulin resistance with high insulin production. Another may have relatively limited beta-cell reserve at a lower body mass. A third may have a monogenic or autoimmune form initially mistaken for type 2 diabetes.

That heterogeneity motivates a more precise classification. Data-driven clustering groups people whose measured features resemble one another. The hope is that clusters will reveal mechanisms, forecast complications, and guide treatment more accurately than one broad label. The risk is that a convenient statistical pattern becomes a biological “type” before it has proved stable or useful.

What current classification does#

The 2026 American Diabetes Association Standards classify diabetes conventionally as type 1 diabetes, type 2 diabetes, gestational diabetes, and specific types due to other causes. The last group includes monogenic syndromes, exocrine pancreatic disease, and drug- or chemical-induced diabetes.

This system is etiologic in some places and descriptive in others. Type 1 diabetes is usually autoimmune beta-cell destruction leading toward severe insulin deficiency, and type 2 diabetes is a nonautoimmune progressive loss of adequate insulin secretion, often on a background of insulin resistance.

Real cases do not always present cleanly. Adults can develop autoimmune diabetes. People with obesity can have type 1 diabetes. Monogenic diabetes may look like mild type 2 disease across several generations. Pancreatitis, pancreatic surgery, cystic fibrosis, hemochromatosis, and medications can produce distinct mechanisms.

Before you subdivide type 2 diabetes, there is a more immediate task: confirm that the broad category is correct. Autoantibodies, C-peptide, and family history can be informative in the right context. So can age, tempo, and ketosis. So can pancreatic history and treatment response.

The five-cluster proposal#

Ahlqvist and colleagues analyzed adults with newly diagnosed diabetes in Swedish cohorts. They used glutamic acid decarboxylase antibodies, age at diagnosis, and body mass index. They used A1C and estimates of beta-cell function and insulin resistance derived from fasting glucose and C-peptide.

The analysis produced five groups:

• Severe autoimmune diabetes included antibody-positive participants and resembled type 1 diabetes.
• Severe insulin-deficient diabetes was antibody negative but had poor metabolic control and low estimated insulin secretion.
• Severe insulin-resistant diabetes had high estimated insulin resistance and a higher observed risk of diabetic kidney disease.
• Mild obesity-related diabetes combined higher body mass with less severe metabolic disturbance.
• Mild age-related diabetes included older participants with comparatively modest metabolic disturbance.

The study replicated the clusters in additional Scandinavian cohorts and linked them with different patterns of treatment and complications, and the severe insulin-deficient group had more retinopathy, while the severe insulin-resistant group had more kidney disease. These were important observations. They did not prove that five is the true number of diseases or that assigning a cluster improves care.

Why the six variables were attractive#

Age, body mass index, and A1C are more accessible than a full metabolic-ward assessment. So are antibodies, fasting glucose, and C-peptide. The HOMA2 estimates attempt to separate insulin secretion from insulin resistance using fasting measurements.

They are proxies, not direct measurements. C-peptide depends on kidney clearance, glucose level, recent food, and medication. HOMA estimates are less precise than clamp methods and can be unstable at extreme values. A1C can be affected by anemia, hemoglobin variants, red-cell turnover, and kidney disease.

The variables are also partly consequences of disease duration and prior treatment. Someone treated before clustering may have a lower A1C, changed weight, or altered glucose and C-peptide. Timing relative to diagnosis matters.

Simple variables make a model feasible. They also constrain what biology it can discover. If inflammation, liver fat, muscle insulin sensitivity, incretin response, social context, or genetic pathways are not measured, clustering cannot organize people around them.

Replication is encouraging but not identical#

Zaharia and colleagues applied the cluster framework in the German Diabetes Study and followed participants with recent-onset disease for five years. The groups showed different metabolic features and complication patterns, providing support outside the original cohorts.

Replication across European, Asian, and other cohorts has often recovered broadly similar severe insulin-deficient, insulin-resistant, obesity-related, and age-related patterns. Yet the proportion assigned to each group varies. Some cohorts recover fewer clusters, and risk associations do not always match in strength or direction.

That variation can reflect ancestry, age structure, and diagnostic practice. It can reflect disease duration, treatment, socioeconomic context, and measurement. It can also show that a clustering algorithm partitions continuous variation rather than discovering fixed natural kinds, and a model can be reproducible enough for research and still not be transportable enough for a clinical label. The test that matters is how it performs in the population where you would use it.

Hard clusters create artificial certainty#

Most algorithms assign each person to one cluster, and a person whose features are almost equally close to two centers receives the same crisp label as someone near the middle of one group. That discards uncertainty.

Mori and colleagues examined classification uncertainty in the German cohort and proposed quantifying how far an individual sits from other possible cluster assignments, and their work highlights that outcome estimates can change when uncertain classifications are handled rather than ignored.

Cluster membership can also change over time. A1C improves, beta-cell function declines, weight changes, and medicines alter fasting measurements. If the label changes after ordinary treatment, it may describe a state rather than an enduring subtype. For some decisions, reporting continuous traits is more honest: degree of insulin resistance, residual insulin secretion, and kidney risk. Adiposity and current metabolic control belong there too. A mixed profile need not be forced into one box.

Genetic clustering asks a different question#

Udler and colleagues grouped type 2 diabetes-associated genetic variants by their relationships with metabolic traits. Their “soft clustering” allowed a variant to contribute to more than one pathway. Five genetic clusters suggested beta-cell, proinsulin, obesity, lipodystrophy-like, and liver or lipid mechanisms.

These are clusters of genetic loci, not the same thing as the five clinical clusters of people. A person's polygenic profile can include contributions from several pathways. Genetics is fixed at conception, while measured metabolic state changes.

The work supports the biological premise that type 2 diabetes can arise through multiple pathways. It does not supply a ready diagnostic panel. Most common variants have small effects, scores depend on ancestry representation, and a pathway score has to improve a decision you actually make to justify its use.

Prediction is not treatment selection#

If one cluster has more kidney disease, you might monitor it more closely. Yet albuminuria, estimated glomerular filtration rate, and blood pressure already identify kidney risk directly. So do smoking, duration, and current glucose control. A cluster has to add information beyond those measures.

The same standard applies to medicines. Retrospective analyses can find that one group had a different average response, but treatment was not randomly assigned by cluster. Confounding by indication, baseline A1C, access, and adherence can create apparent differences.

A decisive test would assign care using a validated subtype strategy and compare it with strong person-centered care. Outcomes could include glycemia, hypoglycemia, and kidney and cardiovascular events. They could include quality of life, treatment burden, and cost. Few such prospective tests exist. Until they do, cluster names should not be converted into medication instructions. They can generate hypotheses and stratify research while ordinary clinical factors guide the care you give today.

Precision care already uses observable features#

Modern type 2 diabetes management is not truly one size fits all. Cardiovascular disease, heart failure, and kidney disease affect medication choice. So do obesity, hypoglycemia risk, and symptoms. So do cost, preferences, and treatment burden. Marked hyperglycemia, catabolism, or suspected insulin deficiency can change urgency.

These variables are actionable because trials and guidelines connect them with treatment benefit; a cluster could eventually organize them more efficiently, but it should be compared with this existing baseline rather than with an imaginary uniform practice.

Precision also includes diagnosis. Finding autoimmune or monogenic diabetes can change therapy, family counseling, and monitoring more directly than assigning a research cluster within confirmed type 2 diabetes.

What the consensus reports conclude#

The ADA and EASD precision-medicine consensus describes precision diagnosis, prevention, treatment, prognosis, and monitoring as related goals. It recognizes promising diabetes subtyping research while emphasizing major evidence gaps, data standards, and diverse representation. It also emphasizes implementation and prospective evaluation.

The framework distinguishes stratification from personalization. A group average can guide a decision, but care still depends on the person in front of you. Conversely, endlessly adding variables does not guarantee a more useful prediction. Clinical utility also includes feasibility. A classification requiring specialized assays, repeated testing, or proprietary software may not outperform a simpler rule once cost, missingness, and access are considered.

How to judge a new subtype paper#

Ask whether the study included all adult-onset diabetes or only antibody-negative type 2 diabetes. Check when variables were measured and what treatment had begun. Look for diverse external cohorts, missing-data handling, uncertainty, and stability over time.

Then separate three claims:

1. The algorithm finds groups with different average characteristics.
2. The groups predict outcomes beyond ordinary risk factors.
3. Assigning the groups improves treatment decisions and health.

Evidence for the first claim does not establish the third. Many subtype headlines cross those steps without telling you.

Finally, check whether the number of clusters was chosen by a prespecified criterion or by interpretability after trying alternatives, and five memorable names can feel biological even when four or six partitions fit almost as well.

A constructive role for clusters now#

Clusters can enrich trials, identify high-risk cohorts, connect clinical patterns with molecular pathways, and reveal that a broad diagnostic category contains different trajectories; they can also make researchers test assumptions that average treatment effects apply uniformly.

For public communication, the most defensible conclusion is that type 2 diabetes is heterogeneous and that several reproducible patterns have been described. The exact labels remain provisional. A person should not be told that a research cluster determines destiny or replaces regular assessment.

Better classification will likely combine categorical diagnoses, continuous physiology, and longitudinal change. It will likely add complications, genetics, and context. The useful end state may not be a new set of five permanent boxes. It may be a dynamic model that answers one decision at a time.

References#

1. ADA 2026 diagnosis and classification standards
2. Ahlqvist adult-onset diabetes cluster study
3. German Diabetes Study five-year cluster outcomes
4. Genetic soft clustering study
5. ADA and EASD precision-medicine consensus
6. Study of cluster classification uncertainty